Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants

Ku, Kühn; Quednow, Boris B.; Thiel, Markus; Falkai, Peter; Maier, Wolfgang; Elger, Christian E.

doi:10.1016/j.yebeh.2003.08.009

Cited by 102 publications

(34 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Kühn et al [108] produced a prospective study of safety and efficacy of citalopram, mirtazepine, and reboxetine (not available in North America) in TLE patients. They performed a post hoc analysis of 75 TLE patients with depression who received standard treatment with one of the above drugs.…”

Section: Management Strategies For Depression In Temporal Lobe Epimentioning

confidence: 99%

Depression in Temporal Lobe Epilepsy: A Review of Prevalence, Clinical Features, and Management Considerations

García

2012

Epilepsy Research and Treatment

View full text Add to dashboard Cite

Depression in temporal lobe epilepsy has been established as a frequent occurrence, and various possible mechanisms for this significant comorbidity have been posited. However, there is still little to guide a clinician in the recognition and management of depression in patients with temporal lobe epilepsy. This is in part due to the lack of consistent findings in earlier studies, which was likely partly due to variabilities in methodology, sampling, and diagnosis of both temporal lobe epilepsy and depression. However, in recent years, significant effort has been made to address these issues and provide a framework for diagnosis and management of depression in this population. The following is a review of the literature, with special emphasis on clinical phenomenology of depressive symptoms, described bidirectional risk between depression and temporal lobe epilepsy, and treatment strategies in the context of potential drug interactions with antiepileptic drugs.

show abstract

Section: Management Strategies For Depression In Temporal Lobe Epimentioning

confidence: 99%

Depression in Temporal Lobe Epilepsy: A Review of Prevalence, Clinical Features, and Management Considerations

García

2012

Epilepsy Research and Treatment

View full text Add to dashboard Cite

show abstract

“…Sertraline [22], [23], citalopram [24], [25], [26], reboxetine [26], mirtazapine [26], and fluoxetine [23] were all shown to be effective in open trials, although there is no randomized-controlled trial to date that shows the superiority of SSRIs over other types of antidepressants or antiepileptic drugs with psychotropic effects [27]. As such, the treatment of interictal depression is recommended to tentatively be similar to that of endogenous depression [27].…”

Section: Discussionmentioning

confidence: 99%

A case of interictal dysphoric disorder comorbid with interictal psychosis: Part of the same spectrum or separate entities?

Morita

Taniguchi

Tamune

et al. 2018

Epilepsy & Behavior Case Reports

View full text Add to dashboard Cite

Depressive disorders in epilepsy often present characteristic clinical manifestations atypical in primary, endogenous depression. Here, we report a case of a 64-year-old woman with right mesial temporal lobe epilepsy, who complained of bizarre, antipsychotic-refractory cenesthetic hallucinations in her interictal phase, and was hospitalized after a suicide attempt. Detailed clinical observations revealed mood symptoms, which led to the diagnosis of interictal dysphoric disorder comorbid with interictal psychosis. Sertraline with low-dose aripiprazole markedly alleviated both depressive and psychotic symptoms. This case suggested that the two diagnostic entities may overlap and that depressive symptoms tend to be concurrent when concurring with psychosis, which hampers the appropriate choice of a treatment option.

show abstract

“…In one large case notes review (n=160), there was no evidence of increased toxicity among patients with glioblastoma multiforme taking an SSRI 64. These and other retrospective studies are reassuring,52 65 but the potential risks of prescribing antidepressants in glioma justify prospective studies 66…”

Section: Unanswered Questionsmentioning

confidence: 96%

Depression in glioma: a primer for clinicians and researchers

Rooney

Brown

Reijneveld

et al. 2013

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

Depression is one of the leading causes of global disability, and a considerable hidden morbidity among patients with glioma. In this narrative review, we summarise what is currently known about depression in glioma, the main unanswered questions and the types of studies that should be prioritised in order to find out. We conclude by calling for a prospective Phase II study of antidepressants in depressed glioma patients, to test methodologies for a multicentre randomised controlled trial.

show abstract

Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants

Cited by 102 publications

References 12 publications

Depression in Temporal Lobe Epilepsy: A Review of Prevalence, Clinical Features, and Management Considerations

Depression in Temporal Lobe Epilepsy: A Review of Prevalence, Clinical Features, and Management Considerations

A case of interictal dysphoric disorder comorbid with interictal psychosis: Part of the same spectrum or separate entities?

Depression in glioma: a primer for clinicians and researchers

Contact Info

Product

Resources

About